Asari, Yusa
Yamasaki, Yoshioki
Tsuchida, Kosei
Suzuki, Kengo
Akashi, Yoshihiro J.
Okazaki, Takahiro
Ozaki, Shoichi
Yamada, Hidehiro
Kawahata, Kimito
Article History
Received: 20 February 2018
Revised: 2 May 2018
Accepted: 8 May 2018
First Online: 18 May 2018
Compliance with ethical standards
:
: Yamasaki Y and Hidehiro Y have received speaking fees from Actelion pharmaceuticals Japan Co., Ltd., Nihon Shinyaku Co., Ltd., Pfizer Japan Inc., GlaxoSmithKline K.K., and Bayer Yakuhin, Ltd. The other authors have disclosed no conflicts of interest.
: The study protocol conformed to the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board of the St. Marianna University School of Medicine (No. 3172).